SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tom D who wrote (19)10/9/1997 1:32:00 AM
From: James Silverman   of 118
 
Tom,
As a clinician, how do you foresee market share shaping up for KOSP? Can it be combined with lower doses of Statins yet still retain excellent efficacy? I've heard a few anectdotes of serious side effects in some statins that perhaps do not show up in their packet inserts. Really just wondering if a nice market is likely to develop for this as a stand alone, in combination with Statins, or both.

Appreciate any insights you may be able to provide.

Regards,
Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News